

Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate

Sara Eyal¹, Francisco S. Chung¹, Mark Muzi², Jeanne M. Link², David A. Mankoff², Amal Kaddoumi¹, Finbarr O'Sullivan³, Mary F. Hebert⁴, and Jashvant D. Unadkat¹

¹Department of Pharmaceutics, University of Washington, Seattle, Washington; ²Division of Nuclear Medicine, University of Washington, Seattle, Washington; ³University College Cork, Cork, Ireland; and ⁴Departments of Pharmacy, Obstetrics and Gynecology, University of Washington, Seattle, Washington

Studies in rodents indicate that the disruption of P-glycoprotein (P-gp) function increases drug distribution into the developing fetus and organs such as the brain. To simultaneously and serially evaluate the effect of P-gp activity and inhibition on the tissue distribution of drugs in a more representative animal model, we tested the feasibility of conducting whole-body PET of the pregnant nonhuman primate (*Macaca nemestrina*). We used ¹¹C-verapamil as the prototypic P-gp substrate and cyclosporine A (CsA) as the prototypic inhibitor. **Methods:** Four pregnant macaques (gestational age, 145–159 d; gestational term, 172 d) were imaged after the intravenous administration of ¹¹C-verapamil (30–72 MBq/kg) before and during intravenous infusion of CsA (12 or 24 mg/kg/h, *n* = 2 each). The content of verapamil and its metabolites in plasma samples was determined using a rapid solid-phase extraction method. The plasma and tissue time–radioactivity concentration curves of ¹¹C were integrated over 0–9 min after each verapamil injection. The tissue or arterial plasma area under the time–concentration curve (AUC_{tissue}/AUC_{plasma}) served as a measure of the tissue distribution of ¹¹C radioactivity. CsA effect on ¹¹C radioactivity distribution was interpreted as P-gp inhibition. The change in the fetal liver AUC ratio served as a reporter of placental P-gp inhibition. **Results:** CsA effect on tissue distribution of ¹¹C radioactivity (AUC ratios) did not increase with the mean blood concentration of CsA, indicating a near-maximal P-gp inhibition. CsA increased maternal brain and fetal liver distribution of ¹¹C radioactivity by 276% ± 88% (*P* < 0.05) and 122% ± 75% (*P* < 0.05), respectively. Changes in other measured tissues were not statistically significant. **Conclusion:** These data demonstrate for the first time, to our knowledge, the feasibility of simultaneous, serial, noninvasive imaging of P-gp activity and inhibition in multiple maternal organs and the placenta in the nonhuman primate. Our findings, consistent with previous data in rodents, indicate that the activity of P-gp in the placenta and the blood–brain barrier is high and that the inhibition of P-gp facilitates drug distribution across these barriers.

Key Words: P-glycoprotein; ¹¹C-verapamil; blood–brain barrier; cyclosporine A; pregnancy

J Nucl Med 2009; 50:798–806

DOI: 10.2967/jnumed.108.059360

The multidrug resistance transporter P-glycoprotein (P-gp) affects drug pharmacokinetics and pharmacodynamics. The importance of P-gp results from its broad substrate selectivity and its strategic localization at critical sites for drug pharmacokinetics, including the blood–brain barrier (BBB), placenta, intestine, liver, and kidneys (1–3). Studies in rodents with genetically or chemically disrupted P-gp function provide evidence for the role of P-gp in the pharmacokinetics of many drugs, including chemotherapeutic, antiretroviral, and cardiac agents (1,3). In each case, the greatest impact of P-gp on drug distribution is at the BBB and the placenta. For example, the chemical inhibition of P-gp function in pregnant mice by the cyclosporine A (CsA) analog PSC833 increases the accumulation of digoxin in the maternal brain 8-fold and in the fetus up to 2.8-fold, but the magnitude of change in the maternal liver, kidneys, and spleen is much less (4).

It has been widely assumed that P-gp in the human BBB and the placental barrier is as important as that in rodents. In addition, it is commonly accepted that inhibition of P-gp may result in a significant increase in tissue distribution of P-gp substrate drugs, thereby increasing the efficacy or toxicity of drugs such as the anti-HIV protease inhibitors and cancer chemotherapeutic agents. However, because species can differ in the level of expression and activity of transporters, it is currently unknown whether this assumption is correct. We have begun to investigate this issue using PET as a noninvasive method to assess P-gp function at the human BBB. Using ¹¹C-verapamil as the P-gp substrate and CsA as the P-gp inhibitor, we found that the brain distribution of ¹¹C radioactivity increases by 88% with average CsA blood concentrations of 2.8 μM (5). This increase is less than that

Received Oct. 23, 2008; revision accepted Jan. 6, 2009.

Address correspondence to: Jashvant D. Unadkat, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195.

E-mail: jash@u.washington.edu

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.

predicted by genetic ablation or CsA inhibition of P-gp in rodents (2,6,7). When rats are studied at the same blood concentration of CsA as that achieved in our human study, the inhibition of P-gp-mediated transport at the BBB is similar (7). However, the maximal magnitude of P-gp inhibition by CsA at the human BBB cannot be assessed because of concerns about CsA toxicity.

Placental P-gp can limit drug delivery to the fetus, such as in the case of the anti-HIV protease inhibitors. Alternatively, the barrier may protect the fetus against the effect of maternal cancer chemotherapy, such as doxorubicin, which has been safely used in pregnancy (8). Thus, more detailed knowledge of P-gp function at the blood-placental barrier is important in drug therapy for pregnant women. However, because of differences in placental physiology, rodents may not be a good model for drug transfer across the human placenta (9). Moreover, because of fetal radiation exposure, the noninvasive measurement by PET of placental P-gp function in humans is not possible. Although we and others have previously shown that the level of P-gp expression in the human placenta decreases with gestational age (10,11), assessment of its function at various gestational ages is not possible in humans. When compared with rodent models, the pregnant macaque provides a more representative model for the study of the maternal-fetal transfer of drugs (12-14). Therefore, using ^{11}C -verapamil as the model P-gp substrate and CsA as the inhibitor, we tested the feasibility of noninvasive, simultaneous PET of P-gp activity and its inhibition in maternal organs and in the placenta in the pregnant macaque, *Macaca nemestrina*. Our hypothesis was that P-gp inhibition by CsA would result in a significant increase in distribution of ^{11}C radioactivity into the tissues most protected by P-gp, that is, the maternal brain and fetus.

MATERIALS AND METHODS

Chemicals and Reagents

Racemic verapamil was purchased from Sigma-Aldrich. D-617 (3,4-dimethoxy- α -[3-(methylamino)propyl]- α -(1-methylethyl)-benzeneacetonitrile) and norverapamil were kindly supplied by Knoll AG. Palladium on alumina (0.5%), anhydrous acetonitrile, and zinc (99%) was purchased from Sigma-Aldrich. Ethanol, anhydrous sodium sulfate, and phosphate-buffered saline (PBS) solution were United States Pharmacopeia products. All other chemicals were purchased from multiple vendors and were of the highest chemical purity available.

Radiopharmaceuticals

^{15}O -water, ^{11}C -CO, and racemic ^{11}C -verapamil were synthesized as previously reported (15). The radiochemical purity of the radiopharmaceuticals was greater than 95%, with the specific activity of ^{11}C -verapamil greater than 57 GBq/ μmol .

Animal Preparation

All experimental procedures were approved by the University of Washington Animal Care Committee. Four pregnant macaques were included in the study (Table 1). After an overnight fast, the animal was sedated with an intramuscular injection of ketamine (10 mg/kg) and atropine (0.04 mg/kg). After the animal was

TABLE 1. Characteristics of Animals at Time of PET Study

Animal no.	Gestational age (d)*	Age (y)	Body weight (kg)	CsA dose (mg/kg/h)
02088	159	14.5	10.3	12
02054	145	8.7	7.6	12
04052	155	12.5	8.2	24
02091	155	8.0	7.6	24
Mean	154	10.9	8.4	
SD	6	3.1	1.3	

*Gestational period of *M. nemestrina* in captivity is 172 d.

placed on a custom-built platform to ensure immobilization in the PET scanner (and also later during the MRI study), it was administered intravenous propofol (5 mg/kg) and intubated. Then, under isoflurane (0.5%–2.0%, v/v) anesthesia, the femoral artery and both femoral veins of the macaques were cannulated for blood sampling, radioactive tracer administration, and CsA infusion, respectively. To reduce spillover of radioactivity from the urinary excretion of the tracers, the animal was equipped with a urinary catheter and well hydrated. Hydration was provided by an intravenous infusion of Normosol-R (a nonpyrogenic, isotonic electrolyte solution) (Hospira, Inc.). Before the animal was positioned in the scanner, a bedside ultrasound was conducted to determine fetal position and heart rate. During the entire study, the animal was monitored noninvasively for blood oxygen saturation, body temperature, and blood pressure.

PET Protocol

All PET studies were performed in a 2-dimensional acquisition mode on a PET scanner (Advance; GE Healthcare) providing 35 image planes over a 15-cm axial field of view (16). To include both the maternal brain and the fetal compartment in the field of view, the animal was positioned on its back, transverse to the scanner axis. This allowed dynamic imaging of the maternal brain, fetus, and all major maternal organs. At the beginning of each study, a 15-min attenuation scan was acquired with a rotating ^{68}Ge source. The attenuation scan was repeated if any significant change in the position of the animal was noted between the substudies. Each substudy is described in detail in Figure 1. The animals were administered 47–73 MBq/kg of ^{15}O -water (5 mL; intravenously, to measure tissue blood flow) as saline; immediately afterward, images were acquired and arterial blood samples (0.5 mL) were obtained (Fig. 1). Blood radioactivity was counted using a γ -counter (Cobra II Auto Gamma; Packard Corp.). At 5–15 min after the ^{15}O -water study, ^{11}C -verapamil (34–72 MBq/kg) was infused intravenously over a period of 1 min, in a total volume of 5–10 mL of isotonic saline containing less than 13% (v/v) (<1.3 mL) ethanol. At the onset of tracer infusion, a 45-min dynamic sequence was started and blood samples (0.5 mL) were taken (Fig. 1). From these samples, aliquots of plasma (100 μL) were counted. A larger volume of blood (3–5 mL) was collected at 1, 4, 8, 14, 20, and 40 min to determine plasma verapamil and metabolite concentrations by solid-phase extraction (SPE). At the completion of the ^{11}C -verapamil scanning, CsA was administered as an infusion (12 or 24 mg/kg/h), for a maximum of 2 h. A second ^{15}O -water imaging study (injected dose, 48–76 MBq/kg) was




FIGURE 1. Schematic of PET protocol. Protocol for 1 animal was modified and shortened.

conducted at approximately 45 min after the initiation of CsA infusion, to measure any changes in the tissue blood flow induced by CsA. After 1 h of CsA infusion, the ¹¹C-verapamil administration was repeated (30–66 MBq/kg), followed by an imaging and blood-sampling sequence identical to the one described above. To measure blood CsA concentrations, blood samples (1 mL) were taken at 1, 4, 8, 14, 20, and 40 min after the start of the second ¹¹C-verapamil infusion. CsA blood concentrations were determined by liquid chromatography–mass spectrometry by the Department of Laboratory Medicine, University of Washington. At the end of the second ¹¹C-verapamil substudy, ¹¹C-CO was administered by inhalation to determine tissue blood volumes (Fig. 1).

This protocol was used in 3 animals. The protocol was modified in the fourth animal, to reduce the compression of the central vessels by the pregnant uterus, as follows: The animal was placed in a lateral decubitus position, the duration of the second ¹¹C-verapamil substudy was shortened to 25 min, ¹¹C-verapamil administration was initiated 30 min into CsA infusion (12 mg/kg/h CsA), and the ¹¹C-CO study was not performed.

Reconstruction of PET Images

After correction for random coincidences, scatter, and attenuation, images were reconstructed onto a 128 × 128 matrix of 35-slice volumes using a 2-dimensional filtered backprojection method with a 12-mm Hanning filter. Standardized uptake value image sets were created by summing the dynamic data from 0 to 5 min for ¹⁵O-water, from 1 to 9 min for ¹¹C-verapamil, and from 4 to 12 min for ¹¹C-CO to facilitate region-of-interest (ROI) placement for image analysis. The tomograph, dose calibrator, and γ -counter were cross-calibrated to express all measurements in common units of radioactivity (μ Ci or MBq).

Image Analysis

Within 2 wk of the PET study, the animal was imaged (in the same position as in the PET scanner) with a 1.5-T MRI instrument (Singa; GE Healthcare). ROIs were identified on T1- and T2-weighted MR images and summed ¹¹C-verapamil images. We used the MR images and PET transmission scans as guides to generate ROIs from contiguous slices to create volumes of interest

for each tissue type using conventional image-processing software (Alice [HIPG]; PMOD, Version 2.9 [PMOD Technologies]). Regions smaller than three times the machine resolution (1.2 cm) were corrected for partial volume (17). Volumes of interest were applied to both the dynamic image sets and the static summed standardized uptake value images for data extraction.

To better facilitate the visualization of the effect of CsA, images from the first-study (without CsA) scans were subtracted from those from the second-study (with CsA) (PMOD) scans, after normalization to injected dose and coregistration, to compensate for the effect of any animal motion between scans. This algorithm allowed visualization on a pixel-by-pixel basis of the net effect of CsA on tissue distribution of ¹¹C radioactivity.

Estimation of Tissue Blood Flow

Image-based arterial-input functions from dynamic ¹⁵O-water studies were created from cardiac ROIs over the maternal heart derived by segmentation (18) and scaled by radioactive measurements of late arterial blood samples. A 1-compartment model (19) using the input function and the dynamic image sequence was used to generate parametric image volumes of blood flow (20). The manual placement of specific tissue ROIs was used to recover the average blood flow for each region.

Quantification of Verapamil and Its Metabolites in Plasma

The amount of radioactive verapamil and its metabolites in the plasma was determined after SPE and high-performance liquid chromatography, as previously described (5,21).

Data and Statistical Analysis

For tissue or arterial plasma area-under-the-curve (AUC_{tissue} and AUC_{plasma} , respectively) analysis, image and plasma data were decay-corrected to the injection time before curve integration. Then the ratio of AUC_{tissue} to AUC_{plasma} was computed. This AUC ratio served as a measure of tissue distribution of ¹¹C radioactivity. The effect of CsA on this distribution was interpreted as P-gp inhibition. Data were expressed as mean \pm SD. The difference between studies performed with or without CsA was

analyzed by the Mann–Whitney test. Significance was set at a *P* value of less than 0.05.

RESULTS

The first 2 animals tolerated the imaging protocol with no adverse events and delivered full-term, viable babies. In these animals, ^{11}C -verapamil injection and CsA infusion did not affect blood pressure or heart rate. The third animal, which had been positioned on its back and treated with 24 mg/kg/h of CsA, experienced significant blood pressure fluctuations at the end of the study, after imaging had been completed. Eight days after the PET study, this animal underwent a C-section to deliver a fetus that was diagnosed as nonviable by ultrasound. The fourth animal was positioned on its left side to avoid central vessel compression, and the imaging protocol was modified. The fourth study was completed successfully, without any adverse events experienced by the mother or her fetus.

The blood concentrations of CsA (Fig. 2) were relatively constant at the 12 mg/kg/h rate but not at the 24 mg/kg/h rate. Although the number of animals was too small to statistically compare the effect of CsA dose on percentage of plasma radioactivity consisting of verapamil or its metabolite, these percentages appeared to be unaffected by CsA dose (Supplemental Table 1; supplemental materials are available online only at <http://jnm.snmjournals.org>); thus, we averaged the results across all 4 animals (Fig. 3). Because of the shortened protocol of the fourth study, results at 40 min represent 3 animals and have not been analyzed statistically.

Our rapid SPE method did not separate 3,4-dimethoxy- α -[3-(methylamino)propyl]- α -(1-methylethyl)-benzeneacetonitrile (D-617) from its *O*-demethylated metabolite, D-717. As in humans, only the dealkylated metabolites, D-617/D-717, and unknown polar metabolites were observed in the plasma of the macaques (Fig. 3). At 40 min after each injection, irrespective of CsA presence or its dose, verapamil accounted for less than 20% of plasma radioactivity. However, at 9 min, verapamil accounted for $48\% \pm 12\%$ and $44\% \pm 13\%$ of total plasma radioactivity in the studies without and with CsA, respectively ($n = 4$, Fig. 3). At the same time, D-617/D-717 accounted for $21\% \pm 7\%$ and $36\% \pm 11\%$ of total plasma radioactivity, respectively ($n = 4$). To minimize the influence of metabolism in the analysis




FIGURE 2. Blood CsA concentration time profiles from time of ^{11}C -verapamil injection ($t = 0$). Legend indicates animal and CsA dose. Rectangle highlights modest change in CsA blood concentration over 0–9 min, the focus of our data analysis. *Animal was studied for only 25 min.

of tissue verapamil radioactivity, we chose to integrate the plasma and the tissue concentration time curves over the first 9 min (AUC_{0-9}). At 5 min, the midinterval of this period, mean blood CsA concentrations were 4.7 and 8.2 μM for the 12 mg/kg/h and 17.9 and 21.0 μM for 24 mg/kg/h infusion rates (Table 2).

For both CsA infusion rates, the profiles of injected dose (ID)-normalized plasma ^{11}C time-activity curves did not differ significantly without and with CsA up to 40 min from verapamil injection (Fig. 4). In each animal, CsA administration increased the distribution of ^{11}C -verapamil into the maternal brain and fetal liver (reporter of placental P-gp activity) (Fig. 4). In the maternal brain, CsA increased the ID-normalized peak concentration, time to peak concentration, and ID-normalized AUC_{0-9} by $209\% \pm 42\%$ ($n = 4$, $P < 0.05$), $833\% \pm 410\%$ ($P < 0.05$), and $238\% \pm 49\%$ ($P < 0.05$), respectively (Supplemental Table 2). The ID-normalized AUC_{0-9} of the fetal liver increased by 108% ($n = 4$, $P < 0.05$) after CsA administration (Supplemental Table 2). CsA did not significantly affect the ID-normalized AUC_{0-9} of other organs, including the maternal liver and gallbladder. The impact of CsA on the uptake of radioactivity into the maternal brain and fetal liver is shown in Figure 5.


A better measure of the effect of CsA on uptake of ^{11}C radioactivity across blood-tissue barriers is obtained when the AUC values of individual organs are normalized by the AUC values of plasma (Fig. 6). CsA effect on AUC ratios did not increase proportionally with the mean blood concentrations of CsA (Table 2). As a result of P-gp inhibition at the BBB of the macaque, the maternal brain distribution of ^{11}C radioactivity increased from 0.92 ± 0.15 to 3.40 ± 0.66 ($276\% \pm 88\%$; $n = 4$, $P < 0.05$). The AUC ratios of the fetal liver across all animals increased from 0.90 ± 0.25 to 1.87 ± 0.34 ($122\% \pm 75\%$; $P < 0.05$, $n = 4$). AUC ratios of other tissues were not significantly affected by CsA. Comparable results were obtained when tissue and plasma concentration-time curves were integrated over the first 0–20 min or 0–40 min from each verapamil administration (Fig. 6). Changes at 40 min were not statistically tested, because only 3 animals continued the imaging study beyond 20 min.

CsA increased mean maternal cerebral blood flow by $18\% \pm 38\%$ (from 1.57 ± 0.57 to 1.65 ± 1.16 mL/mL/min, $n = 3$). On average, CsA decreased placental blood flow by 19%, but intersubject variability was high (SD, 56%).

DISCUSSION

Here we report the first, to our knowledge, simultaneous assessment of in vivo P-gp activity and inhibition in multiple tissues in the macaque. Our study was designed to test the feasibility of whole-body imaging to identify tissues in which inhibition of P-gp activity (by CsA) results in marked changes in tissue distribution of a P-gp substrate drug, ^{11}C -verapamil. As was demonstrated by our studies and those of others, the percentage change induced by

FIGURE 3. Percentage of ^{11}C radioactivity in plasma before and during CsA infusion show that verapamil is rapidly metabolized in pregnant macaques. At 9 min, CsA did not significantly affect plasma radioactivity of verapamil and D-617/D-717 but decreased radioactivity of polar metabolites. At 40 min, less than 20% of total radioactivity was verapamil with or without CsA. Data are expressed as mean \pm SD ($n = 4$). Data without and with CsA (at given time point) were compared using Mann-Whitney test. * $P < 0.05$.



CsA in the tissue distribution of ^{11}C -verapamil radioactivity was interpreted as the magnitude of P-gp inhibition (2,5–7).

Because this is a pilot study that compares P-gp inhibition among different organs, we targeted 2 different blood concentrations of CsA: one that approximates the half-maximal effective concentration (EC₅₀) for P-gp inhibition in the rat (7.2 μM) (7) and the other that is higher than the rat EC₅₀ and predicted to completely inhibit P-gp function (7). Although verapamil undergoes stereoselective metabolism (22,23), the *R* and *S* enantiomers of verapamil have approximately equal affinity for P-gp (24). Thus, P-gp-mediated distribution of ^{11}C -verapamil radioactivity into tissues would be dependent only on the total ^{11}C -racemic verapamil blood concentration and the tissue-specific P-gp activity, making it unnecessary to study the distribution of individual enantiomers.

The metabolism of verapamil was faster in pregnant macaques than it was in humans (Fig. 3) (5) or in male macaques (25) and was most likely enhanced by pregnancy, as a result of CYP3A induction (26,27). The major radioactive metabolites in macaques, similar to those in humans, were ^{11}C -D617/D-717, formed by dealkylation, and polar metabolites, formed by *N*-demethylation. CsA did not change the fraction or the amount of radioactivity present

in plasma as verapamil at 9 min after verapamil administration. By 40 min, verapamil accounted for less than 20% of the total radioactivity. For this reason, and because differential uptake of verapamil and its metabolites into individual tissues can exist, we limited our analysis to the first 9 min after each verapamil injection. Over this period, at least 70% of the observed radioactivity was related to verapamil and D-617/D-717, a P-gp substrate (28). Nevertheless, the contribution of metabolites to total tissue radioactivity did not confound our estimation of P-gp inhibition because AUC ratios and the effects of CsA on tissue radioactivity, with the exception of effects on the maternal gallbladder, were quantitatively comparable between measurements at 9, 20, and 40 min (Fig. 6).

The shape and location of the placenta make it difficult to reliably identify and measure tracer uptake. In addition, a substantial fraction (~50%) of the placenta is maternal or fetal blood (29). The latter is not labeled by ^{11}C -CO. However, the fetal liver is readily identifiable on PET. The substantial fetal hepatic accumulation of verapamil radioactivity served as a readily identifiable reporter of the net placental passage of verapamil into the fetal compartment (tracer concentrations in the extrahepatic fetal tissues were too low to determine their values with confidence). Al-

TABLE 2. Percentage Change in Plasma or Tissue Distribution of ^{11}C Radioactivity Produced by CsA

Animal no.	Blood CsA concentration at 5 min (μM) [*]	ID-normalized AUC ₀₋₉ plasma (% change)	AUC _{tissue} :AUC _{plasma} 0-9 min (% change)									
			Maternal brain	Fetal liver	Maternal liver	Gallbladder	Kidneys	Heart	Lungs	Spine	Spleen	Uterine wall
02088	8.2	-17.3	366.2	153.4	-0.5	76.6	36.4	45.9	45.5	31.5	23.0	22.9
02054	4.7	3.8	164.2	88.8	-12.5	-4.5	19.1	-9.3	6.2	-8.1	12.6	-20.0
04052	21.0	-22.0	322.5	35.8	-3.1	31.8	38.1	23.5	33.5	-6.7	37.8	83.6
02091	17.9	3.4	252.0	208.9	-23.7	-17.5	-7.2	6.2	-3.4	-12.7	-1.1	-16.5
Mean		-8.0	276.2 [†]	121.8 [†]	-10.0	21.6	21.6	16.6	20.5	1.0	18.1	17.5
SD		13.5	88.3	75.4	10.5	42.1	21.0	23.7	22.9	20.5	16.4	48.2

^{*}Approximate midpoint of 0- to 9-min time.

[†] $P < 0.05$.




FIGURE 4. Plasma (A) and tissue (B–L) ¹¹C radioactivity concentration time profiles in representative animal without (▲) and with (△) CsA (12 mg/kg/h). With CsA, these profiles show greater distribution of radioactivity into maternal brain (B) and fetal liver (C) but lesser distribution into maternal liver (D). In maternal gallbladder (E), CsA initially increased accumulation of ¹¹C radioactivity but reduced it at later time points. CsA did not change time–concentration profiles of radioactivity in plasma or other tissues.

though fetal movement between the PET and MRI scans complicated coregistration of PET and MR images, the exclusive concentration of radioactivity in the fetal liver made this organ readily identifiable.

In agreement with previous studies in mice and rats (2,6), the distribution of ¹¹C-verapamil radioactivity (AUC₀₋₉) into the

maternal kidneys, heart, lungs, spleen, and uterus in our study was not significantly affected by CsA (Fig. 6). In contrast, the impact of CsA on P-gp activity was significant at the maternal BBB and placenta. These differences in activity likely reflect higher P-gp expression in these tissues. Our interpretation of tissue P-gp inhibition is based on the assumption that the




FIGURE 5. PET images of pregnant *M. nemestrina* before (A) and during (B) administration of CsA (12 mg/kg/h). PET scans (A and B) are SUV images summed over a period of 1–9 min after ^{11}C -verapamil injection. Images A and B were scaled to the same pixel value. (C) Image produced by pixel-by-pixel subtraction of scan A from scan B. Fetal liver was reporter of ^{11}C radioactivity that crossed placental barrier. Because of P-gp inhibition, CsA significantly increased distribution of ^{11}C radioactivity into maternal brain and fetal liver (yellow to red areas in B and C). In maternal liver, CsA decreased amount of ^{11}C radioactivity (darker area in C). Color scale reflects SUV as shown by thermometer. (D) T2-weighted MR image of the same animal. SUV = standardized uptake value.

combination of verapamil and CsA results in inhibition of P-gp only. This is not an unreasonable assumption because previous studies have shown that verapamil is not a substrate of the multidrug resistance-associated proteins or breast cancer resistance protein and, on the basis of its chemical structure, is unlikely to be a substrate of organic anion transporter families (5). However, we cannot exclude the possibility that in certain organs, verapamil and CsA could interact through organic cation transporters, the novel organic cation transporter 2, or other, yet unidentified efflux and influx transporters (30,31).

The largest effect at the BBB was likely due to the high level of P-gp expression and function at this barrier. At the higher mean CsA blood concentration (19.4 μM), the brain-to-plasma AUC ratio of ^{11}C radioactivity changed 3.9-fold. These results are consistent with the 2.3-fold increase in the cerebrum-to-blood AUC of ^{11}C -verapamil radioactivity in male *Macaca mulatta* after the administration of the CsA analog PSC833 (25). In contrast, our study in rats demonstrated an approximately 12-fold increase in




FIGURE 6. Effect of CsA on distribution (percentage change in $\text{AUC}_{\text{tissue}}/\text{AUC}_{\text{plasma}}$) of ^{11}C radioactivity into maternal brain and fetal liver was large and significant. In contrast, its effect on distribution of ^{11}C radioactivity into other tissues was insignificant. Data are expressed as mean \pm SD ($n = 4$). * $P < 0.05$.

the brain-to-plasma total ^3H radioactivity ratio at comparable mean CsA blood concentrations (17.3 μM) (7). The lower maximal increase in the brain distribution of ^{11}C radioactivity in the pregnant macaques might be explained by species differences in the contribution of BBB P-gp activity to the distribution of ^3H -verapamil radioactivity into the brain, inhibition of an influx transporter by CsA, or pregnancy. However, because a similar degree of inhibition was observed in male, unanesthetized macaques with another P-gp inhibitor, the first explanation appears to be more likely. If this conclusion is extrapolated to humans, the rodent P-gp knockout models may overestimate the potential for P-gp-mediated drug interactions at the human BBB. This may seem at odds with our previous conclusion that the rodent is an excellent predictor of the verapamil–CsA interaction at the BBB (32). However, there is no discrepancy. Although there is an excellent agreement between the interaction observed at the rat and human BBBs at the lower CsA blood concentrations, our data suggest a divergence between the rat and the human as the inhibitor concentration is increased and as P-gp inhibition approaches a maximum. To test this hypothesis, additional drug interaction studies in humans with inhibitors of P-gp more potent than CsA (quinidine, itraconazole) are needed.

At the placental barrier, the significance of P-gp was demonstrated by the 2.2-fold (122%) increase in fetal liver radioactivity after CsA administration. Our results indicate that CsA has a greater inhibitory effect on the efflux of verapamil across the BBB than across the placenta, likely reflecting a tighter P-gp barrier at the brain, at least for the combination of verapamil and CsA. Mean placental blood flow was not significantly affected by CsA and thus could not explain the enhanced distribution of ^{11}C radioactivity across the placenta. The contribution of P-gp to the placental barrier may change with gestational age. We have previously shown that P-gp expression in human placental syncytiotrophoblasts decreases approximately 40-fold with gestational age (10), but it is currently unknown whether

this is paralleled by a change in P-gp function. This study has demonstrated the feasibility of PET in pregnant macaques to serially measure the effect of gestational age on placental P-gp functional activity. In addition, our data suggest that P-gp-mediated drug interactions at the placental P-gp barrier are possible; however, the magnitude of interaction, at therapeutic concentrations of CsA, is expected to be modest. Although CsA is transferred across the placenta (33) and P-gp is expressed in many tissues of the third-trimester human fetus (34), we could not assess the effect of CsA on fetal tissue P-gp activity because the tracer concentrations in the extrahepatic fetal tissues were too low to determine their values with confidence.

In contrast to the effects of CsA on tissue radioactivity in the brain and fetus, with the exception of effects on the gallbladder, CsA did not affect tissue distribution of ^{11}C radioactivity into other tissues such as the liver and kidneys. These data are consistent with the rodent data, in which the contribution of P-gp at these blood-tissue barriers appears to be less than that at the BBB and blood-placental barrier. We speculate that the reduction in gallbladder radioactivity during CsA administration reflects the inhibition of P-gp in liver canaliculi.

CONCLUSION

The current study provides proof of concept that PET can be used in the pregnant macaque to noninvasively and simultaneously assess the impact of P-gp inhibition on the distribution of drugs into multiple tissues. The inhibition of P-gp is tissue-specific, and the greatest impact is at the BBB and the placental barrier, two important barriers affecting drug distribution into the brain and the fetus, respectively. In addition, the maximal inhibition of P-gp at supratherapeutic concentrations of CsA affects brain distribution of ^{11}C -verapamil radioactivity in macaques less than it does in rodent models, in which P-gp function is genetically or chemically ablated. If the macaque is representative of humans, these data suggest that genetic or chemical knockout of P-gp in rodents will overestimate the maximum potential of drug interactions at the human BBB when potent inhibitors of P-gp are studied. To test this hypothesis, additional drug interaction studies in humans, with inhibitors of P-gp more potent than CsA (e.g., quinidine), are needed.

ACKNOWLEDGMENTS

We are indebted to Steve Shoner, Tony Park, Kathryn Bray, Barbara Lewellen, Pam Pham, Thomas Lewellen, Lisa Flint, Jeff Stevenson, Paul Chu, and Jenne Hoard, from the Department of Radiology; Mike Gough, Ed Novak, Pat Delio, Bruce Brown, Keith Vogel, Cliff Astley, and Melinda Young, from WaNPRC; and Dale Whittington, from the Department of Pharmaceutics, for their expert technical assistance. We further thank Andrei Mikeev, Mary Blonski,

Suresh Babu Narahariseti, Brian Kirby, Christopher Enders, Andrew Bostrom, Huixia Zhang, and Xiaohui Wu, from the Department of Pharmaceutics, for their assistance in conducting this study and Duane Bloedow, from the Department of Pharmaceutics, for fruitful discussions. This study was supported by National Institute of Health grants U10HD047892 (Obstetric-Fetal Pharmacology Research Unit Network), P50HD044404, GM032165, and RR00166.

REFERENCES

1. Endres C, Hsiao P, Chung F, Unadkat J. The role of transporters in drug interactions. *Eur J Pharm Sci.* 2006;27:501–517.
2. Hendrikse N, Schinkel A, de Vries E, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. *Br J Pharmacol.* 1998;124:1413–1418.
3. Schinkel A. P-glycoprotein, a gatekeeper in the blood-brain barrier. *Adv Drug Deliv Rev.* 1999;36:179–194.
4. Smit J, Huisman M, van Tellingen O, Wiltshire H, Schinkel A. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. *J Clin Invest.* 1999;104:1441–1447.
5. Sasongko L, Link J, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. *Clin Pharmacol Ther.* 2005;77:503–514.
6. Hendrikse N, Vaalburg W. Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography. *Methods.* 2002;27:228–233.
7. Hsiao P, Sasongko L, Link J, et al. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. *J Pharmacol Exp Ther.* 2006;317:704–710.
8. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. *Reprod Toxicol.* 2006;22:400–410.
9. Carter A. Animal models of human placentation: a review. *Placenta.* 2007;28(suppl A):S41–S47.
10. Mathias AA, Hitti J, Unadkat JD. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. *Am J Physiol Regul Integr Comp Physiol.* 2005;289:R963–R969.
11. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. *Placenta.* 2006;27:602–609.
12. Benveniste H, Fowler JS, Rooney W, et al. Maternal and fetal ^{11}C -cocaine uptake and kinetics measured in vivo by combined PET and MRI in pregnant nonhuman primates. *J Nucl Med.* 2005;46:312–320.
13. Hartvig P, Lindberg BS, Lilja A, Lundqvist H, Långström B, Rane A. Positron emission tomography in studies on fetomaternal disposition of opioids. *Dev Pharmacol Ther.* 1989;12:74–80.
14. Tunlind T, Odinecs A, Pereira C, Nosbisch C, Unadkat J. In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. *Am J Obstet Gynecol.* 1999;180:198–206.
15. Link J, Krohn K, Clark J. Production of [^{11}C]CH₃I by single pass reaction of [^{11}C]CH₄ with I₂. *Nucl Med Biol.* 1997;24:93–97.
16. Lewellen T, Kohlmyer S, Miyaoka R, Kaplan M, Stearns C, Schubert S. Investigation of the performance of the General Electric ADVANCE positron emission tomograph in 3D mode. *IEEE Trans Nucl Sci.* 1996;43:2199–2206.
17. Kohlmyer S, Vesselle H, Miyaoka R, Kaplan M, Lewellen T. Comparison of recovery coefficients for PET based on maximum and average ROI pixel values [abstract]. *Eur J Nucl Med.* 2000;27:1027.
18. O'Sullivan F, Kirrane J, Muzi M, O'Sullivan J, Spence A, Krohn K. Bayesian use of historical data to guide blood input function extraction from dynamic PET studies [abstract]. *J Nucl Med.* 2007;48(suppl 2):157P.
19. Kety S. The theory and applications of the exchange of inert gas at the lungs and tissues. *Pharmacol Rev.* 1951;3:1–41.
20. O'Sullivan F. Locally constrained mixture representation of dynamic imaging data from PET and MR studies. *Biostatistics.* 2006;7:318–338.
21. Unadkat J, Chung F, Sasongko L, et al. Rapid solid-phase extraction method to quantify [^{11}C]verapamil, and its [^{11}C]metabolites, in human and macaque plasma. *Nucl Med Biol.* 2008;35:911–917.
22. Bhatti M, Foster R. Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. *Biopharm Drug Dispos.* 1997;18:387–396.

23. Nelson W, Olsen L. Regiochemistry and enantioselectivity in the oxidative *N*-dealkylation of verapamil. *Drug Metab Dispos.* 1988;16:834–841.
24. Luurtsema G, Molthoff CF, Windhorst AD, et al. (R)- and (S)-[¹¹C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. *Nucl Med Biol.* 2003;30:747–751.
25. Lee YJ, Maeda J, Kusuhara H, et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [¹¹C]verapamil. *J Pharmacol Exp Ther.* 2006;316:647–653.
26. Hebert M, Easterling T, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington Specialized Center of Research study. *Clin Pharmacol Ther.* 2008;84:248–253.
27. Zhang H, Wu X, Wang H, Mikheev A, Mao Q, Unadkat J. Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course. *Mol Pharmacol.* 2008;74:714–723.
28. Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. *J Pharmacol Exp Ther.* 2000;293:376–382.
29. Berglund L, Lilja A, Andersson J, et al. Maternal blood volume in placenta of the rhesus monkey measured in vivo by positron emission tomography. *Gynecol Obstet Invest.* 1991;31:1–7.
30. Grube M, Meyer Z, Schwabedissen H, et al. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). *Circulation.* 2006;113:1114–1122.
31. Treiber A, Schneiter R, Delahaye S, Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. *J Pharmacol Exp Ther.* 2004;308:1121–1129.
32. Hsiao P, Bui T, Ho R, Unadkat J. In vitro to in vivo prediction of P-glycoprotein based drug interactions at the human and rodent blood-brain barrier. *Drug Metab Dispos.* 2008;36:481–484.
33. Venkataramanan R, Koneru B, Wang C, Burckart G, Caritis S, Starzl T. Cyclosporine and its metabolites in mother and baby. *Transplantation.* 1988;46:468–469.
34. van Kalken C, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. *Am J Pathol.* 1992;141:1063–1072.